Fentanyl

Fentanyl is a synthetic opioid analgesic of the phenylpiperidine (anilidopiperidine) class, first synthesized by the chemist Paul Janssen around 1960 ^[1]. It is a full agonist at the mu-opioid receptor and is far more potent than morphine, an attribute that makes it valuable in controlled medical settings and dangerous when misused ^[1][2]. In medicine it is used to induce and maintain anesthesia, to control severe acute pain, to manage breakthrough pain in people who are already tolerant to opioids, and in palliative and end-of-life care ^[1].

Because it is highly lipid-soluble, fentanyl enters the brain quickly and acts rapidly, and it is formulated in many ways to suit different needs ^[1]. Available forms include intravenous injection, transdermal skin patches that release the drug slowly over days, lozenges, buccal and sublingual tablets and films, and nasal sprays ^[1]. In appropriate medical doses it produces strong pain relief; like all opioids it also depresses breathing, and this respiratory depression is the effect responsible for fatal overdoses ^[2][3].

The drug's potency has driven a public-health crisis. Illicitly manufactured fentanyl, often mixed into heroin, counterfeit pills or other drugs, has become a dominant cause of overdose deaths; United States surveillance recorded steep rises in deaths involving synthetic opioids, driven largely by illicit fentanyl ^[4]. Even very small amounts can be lethal, and the opioid antagonist naloxone is used to reverse overdoses ^[2][3].

Fentanyl is a tightly controlled medicine, listed as a Schedule II controlled substance in the United States and under equivalent controls elsewhere, reflecting its accepted medical use alongside a high potential for abuse and dependence ^[1]. It also appears on the World Health Organization list of essential medicines for its role in anesthesia and pain care ^[1].

The one risk that matters most is respiratory depression; fentanyl can slow or stop breathing, and that is how nearly every fatal overdose happens. Because the effective dose is so small, the difference between a dose that relaxes someone and a dose that kills them can be a few grains of powder, which is exactly why illicit product is so lethal; there is no way to eyeball the strength of street fentanyl, and it is now commonly pressed into fake oxycodone or Xanax pills and cut into heroin and cocaine.

Mixing it with other downers is especially deadly: benzodiazepines like alprazolam, alcohol, and the veterinary sedative xylazine all pile onto the same respiratory brakes, and xylazine will not respond to naloxone at all. Repeated use builds tolerance and physical dependence fast, and stopping brings a rough opioid withdrawal.

High intravenous doses can trigger chest wall rigidity (sometimes called wooden chest) that makes a person hard to ventilate. It can also interact with serotonergic drugs to raise serotonin syndrome risk, and drugs that block the CYP3A4 enzyme can push its levels up.

Naloxone (Narcan) does reverse it, but fentanyl is potent and relatively long-lasting while naloxone wears off in 30 to 90 minutes, so more than one dose is often needed and the person can slip back into overdose after the first dose fades; anyone reversing an overdose should call emergency services and stay with the person. Pharmaceutical fentanyl is a Schedule II controlled substance in the United States, while the clandestine analogs like carfentanil, which is thousands of times stronger than morphine, are treated as Schedule I.

Fentanyl is metabolized by CYP3A4 and is highly susceptible to pharmacokinetic interactions. When coadministered with xylazine, an alpha-2 agonist veterinary sedative increasingly found as a contaminant in illicit opioid supplies, xylazine reduces plasma fentanyl concentrations by approximately 8-fold at 15 minutes post-administration ^[5]; this represents altered absorption and distribution rather than enzymatic inhibition. Despite theoretical concern over CYP3A4 inhibitors such as ketoconazole, clarithromycin, and protease inhibitors, published clinical studies documenting quantitative interactions between fentanyl and these agents in humans remain scarce; the FDA label alerts to the risk, but magnitude and clinical management strategies for these interactions lack robust literature support.

Checking a whole stack? Run it through interactions + stacks.